Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Starting soon · Phase 4

Conditions studied: Knee Arthritis, Knee Osteoarthritis

In brief

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

Key facts

Study ID

NCT07624526

Run by

Emory University

People needed

75

Starts

2026-07-01

Expected to finish

2028-08-01

Last updated by the study team

2026-06-03

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee.
• Patients between the ages of 18 and 95 years.

You may not qualify if…

• Patients with concurrent and significant injuries to other bones or organs.
• Patients with local infections.
• Minors unable to provide informed consent for participation in the study.
• Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.
• Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk.
• Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery.
• Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction
• Patients with active peptic ulcer disease.
• Patients neurological or psychiatric diseases, potentially influencing pain perception
• Patients who are pregnant.
• Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids.
• Patients who are unable to take NSAIDs.
• Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID).
• Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%.
• Patients currently taking CYP3A inhibitors

Where it is running

• Emory Clinic — Atlanta, Georgia, United States
• Emory Clinic at Executive Park — Atlanta, Georgia, United States
• Emory Orthopaedics and Spine Center — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.